Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Immuneering Corp executive Mallory Morales, SVP Finance and Chief Accounting Officer, received a grant of stock options covering 140,000 shares of Class A common stock on February 3, 2026. The options have an exercise price of $4.91 per share and were granted at no cost.
The option award vests in equal monthly installments over four years starting February 1, 2026 and will be fully vested and exercisable on January 1, 2030. Following this grant, Morales beneficially owns 140,000 stock options directly.
Immuneering Corp’s chief people officer receives new stock options grant. Leah R. Neufeld was awarded stock options covering 140,000 shares of Class A common stock on February 3, 2026, with an exercise price of $4.91 per share and no purchase price for the options themselves.
The options vest in equal monthly installments over four years starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. Following this grant, Neufeld beneficially owns 140,000 derivative securities directly through this option award.
Immuneering Corp reported that President and CEO Benjamin J. Zeskind received a grant of stock options on February 3, 2026. The award covers 688,000 options with an exercise price of $4.91 per share, each option linked to Class A common stock.
According to the filing, the options vest in equal monthly installments over four years starting on February 1, 2026, and will be fully vested and exercisable by January 1, 2030. Following this grant, Zeskind beneficially owns 688,000 derivative securities directly.
Benjamin J. Zeskind reports beneficial ownership of 4,357,807 shares of Immuneering Corporation Class A common stock, representing 6.6% of the class. This ownership is calculated as of December 31, 2025, based on 64,569,967 shares outstanding as of November 5, 2025, as disclosed in Immuneering’s Form 10-Q. The position includes 2,312,852 shares held directly, 1,150,028 shares underlying stock options exercisable on or before March 1, 2026, and 894,927 shares held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse is sole trustee. Zeskind has sole voting and dispositive power over 3,462,880 shares and shared voting and dispositive power over 894,927 shares.
Immuneering Corp’s Chief Business Officer, Harold Eugene Brakewood, reported buying Class A common stock. On January 16, 2026, he purchased 5,250 shares of Immuneering’s Class A common stock at a price of $4.76 per share, coded as an open-market or private purchase (transaction code "P").
After this transaction, Brakewood beneficially owned a total of 11,050 shares of Immuneering Class A common stock, held in direct ownership.
Immuneering Corp director Thomas J. Schall reported buying additional Class A common stock. On January 15, 2026, he purchased 21,645 shares of Immuneering Class A common stock in an open-market transaction coded as a purchase. The weighted average price was $4.6681 per share, with individual trades executed through a broker-dealer at prices ranging from $4.61 to $4.69. Following this transaction, Schall directly beneficially owns 74,530 shares of Immuneering Class A common stock.
Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, reported buying Class A Common Stock in an insider transaction. On January 15, 2026, he purchased 2,298 shares at a weighted average price of $4.57 per share through a broker-dealer.
After this purchase, Hall directly beneficially owns 376,496 shares of Immuneering Class A Common Stock. The trade was executed in multiple lots at prices ranging from $4.57 to $4.571, with the weighted average price reported in the filing.
Immuneering Corp received an updated ownership report from Empery Asset Management and affiliated reporting person Ryan M. Lane. They report beneficial ownership of 3,250,775 shares of Class A common stock, equal to 4.99% of the company’s outstanding shares. This total includes 575,825 shares issuable upon exercise of warrants held by funds managed by Empery.
The percentage is based on 64,569,967 shares of common stock outstanding as of November 5, 2025, as disclosed in Immuneering’s Form 10-Q. The warrants contain a 4.99% “Blocker” provision that prevents the reporting persons from exercising warrants if it would push their beneficial ownership above 4.99% of Immuneering’s outstanding common stock. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Immuneering Corp's Chief People Officer, Leah R. Neufeld, reported buying 2,626 shares of the company's Class A common stock on January 13, 2026. The purchase was recorded at a price of $4.153 per share and is classified as a direct acquisition. After this transaction, Neufeld directly holds 25,970 Class A common shares of Immuneering Corp.
Immuneering Corp director Peter Feinberg reported an indirect purchase of Class A common stock on January 12, 2026. Through S4K Investments LLC, he acquired 20,000 shares at a weighted average price of $4.3452 per share, with individual trade prices ranging from $4.315 to $4.38.
After this transaction, Feinberg beneficially owned 135,441 Class A shares indirectly as general partner of S4K Investments LLC. He also held 156,766 shares directly, plus indirect holdings of 392,242 shares as general partner of PF Associates L.P. and 476,615 shares as general partner of PEF LLC.